BioCryst Pharmaceuticals Inc BCRX
News
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
BioCryst Appoints Dr. Donald Fong Chief Medical Officer
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst to Present at Upcoming Investor Conferences
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst to Report Second Quarter 2024 Financial Results on August 5
ORLADEYO® (berotralstat) Approved in Peru
Pharvaris shares surge as treatment for severe swelling meets clinical trial goal